Today: 15 July 2026
Zhongji Innolight (SHE:300308) $7 Billion Hong Kong Plan Would Equal 84% of Its Asset Base
15 July 2026
3 mins read

Zhongji Innolight (SHE:300308) $7 Billion Hong Kong Plan Would Equal 84% of Its Asset Base

Hong Kong, July 15, 2026, 22:09 (HKT).

  • The reported sale equals about 3.7% of Innolight’s market value, but 1.34 times its first-quarter shareholder equity, calculations based on market data and company filings show.
  • Even at a 47% discount to its Shenzhen close, modeled dilution would be about 6.4%, assuming the entire $7 billion comes from new shares.

Zhongji Innolight is close to Chinese regulatory approval for a Hong Kong share sale of about $7 billion, people familiar with the matter said. At Wednesday’s Shenzhen close, a sale made entirely of new stock at the same price would dilute existing holders by roughly 3.5%, while raising gross proceeds equal to 84% of the company’s assets at the end of March.

Clearance from the China Securities Regulatory Commission would allow the optical-transceiver maker to seek a Hong Kong exchange hearing as soon as this week. The size, timing and final approvals may change, the people said. Innolight and the regulator did not immediately respond to requests for comment. The fundraising target had previously risen from about $5 billion after strong investor interest, according to a report last month.

Innolight’s shares closed at 1,169.31 yuan, down 1.24%, after gaining more than 90% this year. Its market value is about 1.3 trillion yuan. Using the yuan’s current level of roughly 6.8 per dollar, the reported offering converts to about 47.6 billion yuan.

Reference pointLatest reported valueCNY47.6 billion proceeds
Market valueCNY1.30 trillion3.7%
CashCNY12.21 billion3.9 times
Equity attributable to shareholdersCNY35.59 billion1.34 times
Total assetsCNY56.58 billion84%

That arithmetic shifts the investor question from dilution to capital allocation. If the full amount were raised through primary shares and retained by Innolight, its book equity could more than double before fees. The reports did not disclose the primary-secondary mix or how the money would be spent, and a public prospectus has not yet set out final terms.

The first-quarter accounts show a real pull on funding, though not yet on the scale of the proposed deal. Prepayments for materials jumped more than tenfold to 1.49 billion yuan, construction in progress rose 66% to 2.36 billion yuan and investing cash outflow reached 1.95 billion yuan as Innolight expanded capacity. At that quarterly pace, the reported gross proceeds would cover just over six years of investing outflow.

Management’s latest comments suggest it wants capacity in place before demand arrives. “Orders on hand already cover all of 2026,” Vice President and Board Secretary Wang Jun said in a July 12 investor-call record translated from Chinese, adding that some orders extend into 2027. Innolight has not released a first-half forecast, but Wang said rumours of a severe second-quarter shortfall had “no basis” and that gross margin was expected to remain stable.

Supply, rather than orders, appears to be the immediate constraint. Optical and electrical chips and printed circuit boards remain tight, according to the company, which has used long-term contracts and advance payments to secure supply. Wang said reported 2027 price cuts were exaggerated and that few producers could deliver next-generation 1.6-terabit and 800-gigabit modules in volume.

The harder issue is the H-share discount, the gap between Hong Kong-listed shares of mainland firms and their onshore stock. Victory Giant Technology (SHE:300476) priced its April Hong Kong sale 47% below its Shenzhen close. Applying that precedent to Innolight, and assuming a fully primary deal with no fees or additional allotment option, produces the following range:

Discount to Innolight’s Shenzhen closeApproximate new sharesPost-deal dilution
0%41 million3.5%
20%51 million4.3%
47%77 million6.4%

Victory Giant still raised $2.6 billion and closed 50.1% above its offer price on debut, narrowing its discount to the Shenzhen shares to about 17%. Winston Ma, executive director of the Global Public Investment Funds Forum, said at the time that top-end pricing and the full exercise of an upsize option showed deep demand for advanced Chinese manufacturing listings, adding that “the trend shows no sign of slowing down” unless war uncertainty deepened. Reuters

But Innolight’s attractive dilution math rests on terms that remain undisclosed. A deeper discount would require more new shares, while a large secondary component would send less cash to the company. Approval could be delayed, the sale could shrink, and a cheaper Hong Kong price could put pressure on the Shenzhen valuation. Demand may also cool or supply shortages could hold back shipments. Innolight’s July 12 call record explicitly said management’s comments were not an earnings forecast or formal guidance.

At the reported size, the Innolight offering would exceed Victory Giant’s April sale by about $4.4 billion and rank among Hong Kong’s biggest listings in years. For investors, the issue price and the amount of primary capital now matter more than the regulatory milestone alone. They will show whether Hong Kong is funding the next phase of capacity or setting a lower valuation anchor for the shares.

Michał Rogucki is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic developments. A graduate of Humboldt University of Berlin, he previously worked in investment research and market analysis before transitioning to financial journalism. He covers the trends and events that matter most to investors worldwide.

Stock Market Today

  • Nuvalent Moves to Delist Class A Shares from Nasdaq
    July 15, 2026, 10:32 AM EDT. Nuvalent, Inc. (NASDAQ: NUVL) has filed Form 25 to take its Class A common stock off the Nasdaq Stock Market. Nasdaq certified the filing meets SEC rules. The delisting is set to take effect July 15, 2026. Form 25 is the SEC form used to remove a stock under Section 12(b) of securities law. The company is based in Cambridge, Massachusetts.
Angelini wraps $4.1 billion buyout of Catalyst Pharmaceuticals (NASDAQ:CPRX) at 9x projected 2026 EBITDA
Previous Story

Angelini wraps $4.1 billion buyout of Catalyst Pharmaceuticals (NASDAQ:CPRX) at 9x projected 2026 EBITDA

Intel (NASDAQ:INTC) Turns a $400 Million High-NA Tool Into a Manufacturing Hedge
Next Story

Intel (NASDAQ:INTC) Turns a $400 Million High-NA Tool Into a Manufacturing Hedge

Go toTop